Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISAGE-TAVI AF: Edoxaban vs VKA after TAVI in atrial fibrillation
jRCTs031180144Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Randomised, single-blind trial of edoxaban in Atrial fibrillation (AFib) and aortic valve disease (AVD) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Net Adverse Clinical Events (NACE, ISTH major bleeding composite) and Major bleeding (ISTH definition). Started Apr 2017; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)aortic valve disease (AVD)
Beyond the preview
Go deeper on jRCTs031180144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180144.